These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 29407318)

  • 21. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
    Bao Y; Zhao J; Li ZZ
    Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
    Xiao H; Li L; Pang Y; Wu Y; Jiang Z; Liu Z; Wu J; Xiao Y; Huang F; Liu Q; Zhang H; Luo Y; Huang H
    Ann Hematol; 2018 Dec; 97(12):2479-2490. PubMed ID: 30078144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed/refractory acute myeloid leukemia.
    Sun Y; Zhang J; Long B; Zhang X; Wen R; He Y; Li X
    Neoplasma; 2021 Nov; 68(6):1351-1358. PubMed ID: 34641697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
    Wang L; Xu J; Tian X; Lv T; Yuan G
    Acta Haematol; 2019; 141(1):43-53. PubMed ID: 30517910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
    Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
    Kohrt HE; Patel S; Ho M; Owen T; Pollyea DA; Majeti R; Gotlib J; Coutre S; Liedtke M; Berube C; Alizadeh AA; Medeiros BC
    Am J Hematol; 2010 Nov; 85(11):877-81. PubMed ID: 20872554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia.
    Wang YX; Wang A; Su YF; Wang J; Li YH; Li F; Jing Y; Xu L; Wang YZ; Zheng X; Gao CJ; Hu LD; Gao XN; Liu DH
    Front Immunol; 2024; 15():1409302. PubMed ID: 39221255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
    Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
    Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
    Stelljes M; Middeke JM; Bug G; Wagner-Drouet EM; Müller LP; Schmid C; Krause SW; Bethge W; Jost E; Platzbecker U; Klein SA; Schubert J; Niederland J; Kaufmann M; Schäfer-Eckart K; Schaich M; Baldauf H; Stölzel F; Petzold C; Röllig C; Alakel N; Steffen B; Hauptrock B; Schliemann C; Sockel K; Lang F; Kriege O; Schaffrath J; Reicherts C; Berdel WE; Serve H; Ehninger G; Schmidt AH; Bornhäuser M; Mikesch JH; Schetelig J;
    Lancet Haematol; 2024 May; 11(5):e324-e335. PubMed ID: 38583455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
    Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
    Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report.
    Drozd-Sokolowska J; Dwilewicz-Trojaczek J; Tormanowska M; Karakulska-Prystupiuk E; Sachs W; Halaburda K; Urbanowska E; Gierej B; Basak GW; Wiktor-Jedrzejczak W
    Transplant Proc; 2020 Oct; 52(8):2548-2550. PubMed ID: 32571713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
    Hatsumi N; Miyawaki S; Yamauchi T; Takeshita A; Komatsu N; Usui N; Arai Y; Ishida F; Morii T; Kano Y; Ogura M; Machida S; Nishii K; Honda S; Ohnishi K; Naoe T;
    Int J Hematol; 2019 Apr; 109(4):418-425. PubMed ID: 30725360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
    Giralt S; Estey E; Albitar M; van Besien K; Rondón G; Anderlini P; O'Brien S; Khouri I; Gajewski J; Mehra R; Claxton D; Andersson B; Beran M; Przepiorka D; Koller C; Kornblau S; Kørbling M; Keating M; Kantarjian H; Champlin R
    Blood; 1997 Jun; 89(12):4531-6. PubMed ID: 9192777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
    Hütter-Krönke ML; Benner A; Döhner K; Krauter J; Weber D; Moessner M; Köhne CH; Horst HA; Schmidt-Wolf IG; Rummel M; Götze K; Koller E; Petzer AL; Salwender H; Fiedler W; Kirchen H; Haase D; Kremers S; Theobald M; Matzdorff AC; Ganser A; Döhner H; Schlenk RF
    Haematologica; 2016 Jul; 101(7):839-45. PubMed ID: 27036160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
    Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
    Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS
    Leuk Res; 2011 Mar; 35(3):301-4. PubMed ID: 21109304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
    Jaglal MV; Duong VH; Bello CM; Al Ali NH; Padron E; Fernandez HF; List AF; Lancet JE; Komrokji RS
    Leuk Res; 2014 Apr; 38(4):443-6. PubMed ID: 24439565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.